LALinda Al-Hassany

Linda Al-Hassany

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linda Al-Hassany has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Antoinette MaassenVanDenBrink

    Division of Vascular Medicine and Pharmacology, Erasmus MC University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands

    4 shared publications
  • A.H. Jan Danser

    Division of Vascular Medicine and Pharmacology, Rotterdam

    2 shared publications
  • Antoinette MaassenVanDenBrink

    Division of Vascular Medicine and Pharmacology, Rotterdam

    2 shared publications
  • A. MaassenVanDenBrink

    Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam, 3015 GD, the Netherlands

    1 shared publication
  • Alexander H Jan Danser

    Division of Vascular Medicine and Pharmacology, Department of Internal Medicine Erasmus University Medical Center Rotterdam the Netherlands

    1 shared publication
  • Angela Verzina

    Neurological Clinic, S. Maria Misericordia Hospital, Department of Medicine, University of Perugia, 06129 Perugia, Italy

    1 shared publication

Latest Publications

  • Open Access

    Association between migraine and angiogenic biomarkers in women with suspected or confirmed hypertensive disorders of pregnancy

    by Linda Al-Hassany, Noor R.A. Bruijn, Langeza Saleh, Rugina I. Neümañ, Britt W.H. van der Arend, Anna C.M. Kluivers, Gisela M. Terwindt, Willy Visser, A.H. Jan Danser, Antoinette MaassenVanDenBrink

    Aim: Migraine is associated with increased odds of hypertensive disorders of pregnancy (HDP). Elevated soluble Fms-like tyrosine kinase-1 (sFlt-1), decreased placental growth factor (PlGF), and upregulated sFlt-1/PlGF ratios are biomarkers of preeclampsia-related complications. Our primary objective was to examine the effect of migraine on sFlt-1, PlGF, and their ratio within subgroups of women with different HDP diagnoses. Our secondary objective was to evaluate the interrelationship between migraine and these biomarkers in the overall cohort with suspected or confirmed HDP. Methods: We evaluated pregnant women with suspected or confirmed HDP in whom sFlt-1, PlGF and their ratio were measured during index pregnancy. Migraine diagnoses before/during index pregnancy were retrospectively assessed according to ICHD-3 criteria. Both, descriptive and adjusted analyses were performed, comparing women with and without migraine. For the latter analyses, linear regression analyses were conducted for the log-transformed sFlt-1 levels, PlGF levels and their ratio, while adjusting for gestational age, maternal age, and smoking status. Results: Among 234 women (mean age 32 years, SD = 5), 91 had (a history of) migraine. No significant association between migraine and the log-transformed biomarkers was observed in women with and without migraine across HDP groups, also when adjusting for confounding factors (adjusted estimates of the sFlt-1/PlGF ratio: β = −0.2 [95% CI: −1.0–0.6] for women with preeclampsia or hemolysis, elevated liver enzyme levels, and low platelet levels syndrome, β = -0.8 [95% CI: −2.0–0.4] for gestational hypertension, and β = −0.1 [95% CI: −0.7–0.4] for those without HDP). Secondary analyses showed that, when pooling the overall study population, women with migraine had lower sFlt-1 levels and sFlt-1/PlGF ratios compared to women without migraine. Adjusted analyses in the overall study population instead showed that migraine was not associated with significant changes in log sFlt-1 levels ( β = −0.2 [95% CI: −0.5–0.04]), but rather with higher log PlGFs levels ( β = 0.3 [95% CI: 0.03–0.6]) and lower log sFlt-1/PlGF ratios ( β = −0.5 [95% CI: −1.0 – −0.08]). Conclusions: Results of this study do not support enhanced angiogenic imbalance by migraine status within HDP groups. As a consequence, interpretation of sFlt-1 and PlGF might not require modification according to migraine status within different HDP diagnoses. The findings observed in the overall cohort require cautious interpretation; whether migraine influences magnitude of angiogenic dysregulation warrants prospective investigation.

  • Placebo Response in Acute and Prophylactic Treatment of Migraine

    by N.R.A. Bruijn, E.M. Huessler, A. MaassenVanDenBrink, R. Fronczek, H.C. Diener, M D Ferrari, L. Al-Hassany


  • Distinguishing Description, Prediction, and Causal Inference

    by Chisato Ito, Linda Al-Hassany, Tobias Kurth, Toivo Glatz

    This primer introduces the domains into which the aims of quantitative health research generally fall and provides tools to improve the methodological quality of observational clinical and population-based research articles-with a special focus on the field of neurology. Generally, research questions can be categorized into one of the following 3 data science domains: description, prediction, and causal inference. A descriptive question aims to quantify and describe the frequency and distribution of a given health condition in a certain population at or during a specific time. A predictive question aims to estimate either the probability of the presence of a given disease or health condition in an individual (diagnostic prediction) or the probability of an individual developing a disease of interest over a specified period (prognostic prediction). A causal question aims to estimate the causal effect of interest (estimand) of an exposure or intervention on an outcome in a given population. Depending on the research question, estimands could be the total causal effect, a mediated indirect effect, or effect (measure) modification by third variables, among others. Each of these domains comes with its own set of research methods, study designs, reporting guidelines, scientific language, strengths, and limitations, whereby the correct attribution of a research domain will have an impact in 3 ways: i) help authors to formulate appropriate research questions and choose and implement suitable study designs and methods; ii) allow reviewers and editors to assess studies with an increased focus on their clinical relevance, methodological advances, and novelty and quality of clinical evidence; and iii) facilitate clear communication of findings and clinical implications to the broader research community in neurology and related fields.


  • Open Access

    FUPEC study, a prospective open-cohort on severe pre-eclampsia and cardiovascular risk factors based in the Netherlands

    by Marte F van der Bijl, Linda Al-Hassany, Anne I Wijtzes, Koen Verdonk, Johannes J Duvekot, Jeanine Roeters van Lennep

    Purpose: The FUPEC (Follow-Up Pre-EClampsia) study aims to investigate the presence and development of cardiovascular risk factors, cardiovascular disease, as well as cardiovascular health following a pregnancy complicated by severe pre-eclampsia. Participants: The FUPEC study is an open-cohort study conducted within routine care at the FUPEC clinic at Erasmus Medical Center in the Netherlands. This clinic is specifically designed for the cardiovascular follow-up of patients who have experienced severe pre-eclampsia. Women with a history of severe pre-eclampsia are invited to the FUPEC clinic at 6 weeks, 3 months, 1 year and every 2 years thereafter postpartum until they are 50 years of age. Clinical and biochemical data are routinely collected, encompassing pregnancy characteristics and outcomes, anthropometric measurements, cardiovascular risk factors, cardiovascular health scores, carotid intima-media thickness—including vascular age and ambulatory blood pressure measurements. Additionally, blood and urine samples are collected and stored in a biobank. Findings to date: The first patient was enrolled in April 2011. As of March 2024, a total number of 1268 women have been enrolled in the FUPEC study, with an annual enrolment rate of 100–150 new patients. At inclusion, women had a median age of 33.5 years (IQR 30.1–37.9). At their first FUPEC visit, women were a median of 4.9 months (1.9–29.4) after delivery. At the first visit, the median body mass index was 25.7 (IQR 23.0–29.9) kg/m 2 , 23.4% of participants were using antihypertensive medication and 6.4% were smoking. Preliminary analyses of 24-hour blood pressure patterns and carotid intima-media thickness have previously been conducted on a subset of the cohort, with details provided in the ‘Findings to Date’ section. Future plans: The FUPEC cohort serves as a robust clinical data source and biobank that can be used for future studies and collaborative research answering, for example, questions on the aetiology, risk factors and short-term and long-term complications of pregnancies complicated by severe pre-eclampsia. Since the FUPEC cohort is integrated with routine care, there is no strict completion of data collection, allowing for flexible data acquisition.


  • Migraine and Cardiovascular Risk in Women

    by Linda Al-Hassany, Antoinette MaassenVanDenBrink

  • Open Access

    Sex-Specific Association of Cardiovascular Risk Factors With Migraine

    by Linda Al-Hassany, Cevdet Acarsoy, M. Kamran Ikram, Daniel Bos, Antoinette MaassenVanDenBrink

    Although several lines of evidence suggest a link between migraine and cardiovascular events, less is known about the association between cardiovascular risk factors (CVRFs) and migraine. This knowledge is clinically important to provide directions on mitigating the cardiovascular risk in patients with migraine. We hypothesized that CVRFs are associated with a higher migraine prevalence. Therefore, our primary objective was to investigate sex-specific associations between CVRFs and lifetime prevalence of migraine. We performed cross-sectional analyses within an ongoing population-based cohort study (Rotterdam Study), including middle-aged and elderly individuals. By means of (structured) interviews, physical examinations, and blood sampling, we obtained information on the lifetime prevalence of migraine and the following traditional CVRFs: current smoking, obesity, hypercholesterolemia, hypertension, and diabetes mellitus. Similarly, we obtained information on quantitative component data on these CVRFs, including pack-years of smoking, lipid levels, systolic and diastolic blood pressure (BP), body mass index, and fasting glucose levels. Patients with migraine were age-matched to individuals without migraine, and we performed conditional logistic regression analyses to investigate the sex-stratified association of CVRFs with migraine. In total, 7,266 community-dwelling middle-aged and elderly persons were included (median age 66.6 [IQR 56.4-74.8] years, 57.5% females). The lifetime prevalence of migraine was 14.9%. In females, current smoking (odds ratio (OR) 0.72, 95% CI 0.58-0.90), more pack-years (OR per SD increase 0.91, 95% CI 0.84-1.00), diabetes mellitus (OR 0.74, 95% CI 0.56-0.98), and higher fasting glucose levels (OR per SD increase in glucose 0.90, 95% CI 0.82 - 0.98) were all related to a lower migraine prevalence while a higher diastolic BP related to a higher migraine prevalence (OR per SD increase 1.16, 95% CI 1.04-1.29). In males, no significant associations between CVRFs and migraine were observed. Traditional CVRFs were either unrelated or inversely related to migraine in middle-aged and elderly individuals, but only in females. In males, we did not find any association between CVRFs and migraine. Because only an increased diastolic BP was related to a higher migraine prevalence in females, our study contributes to the hypothesis that migraine is not directly associated with traditional CVRFs. Future studies are warranted to extrapolate these findings to younger populations.


  • Open Access

    Functional Analysis of TRPA1, TRPM3, and TRPV1 Channels in Human Dermal Arteries and Their Role in Vascular Modulation

    by Eduardo Rivera-Mancilla, Linda Al-Hassany, Heleen Marynissen, Dorien Bamps, Ingrid M. Garrelds, Jérôme Cornette, A. H. Jan Danser, Carlos M. Villalón, Jan N. de Hoon, Antoinette MaassenVanDenBrink

    Transient receptor potential (TRP) channels are pivotal in modulating vascular functions. In fact, topical application of cinnamaldehyde or capsaicin (TRPA1 and TRPV1 channel agonists, respectively) induces “local” changes in blood flow by releasing vasodilator neuropeptides. We investigated TRP channels’ contributions and the pharmacological mechanisms driving vasodilation in human isolated dermal arteries. Ex vivo studies assessed the vascular function of artery segments and analyzed the effects of different compounds. Concentration–response curves to cinnamaldehyde, pregnenolone sulfate (PregS, TRPM3 agonist), and capsaicin were constructed to evaluate the effect of the antagonists HC030031 (TRPA1); isosakuranetin (TRPM3); and capsazepine (TRPV1). Additionally, the antagonists/inhibitors olcegepant (CGRP receptor); L-NAME (nitric oxide synthase); indomethacin (cyclooxygenase); TRAM-34 plus apamin (K+ channels); and MK-801 (NMDA receptors, only for PregS) were used. Moreover, CGRP release was assessed in the organ bath fluid post-agonist-exposure. In dermal arteries, cinnamaldehyde- and capsaicin-induced relaxation remained unchanged after the aforementioned antagonists, while PregS-induced relaxation was significantly inhibited by isosakuranetin, L-NAME and MK-801. Furthermore, there was a significant increase in CGRP levels post-agonist-exposure. In our experimental model, TRPA1 and TRPV1 channels seem not to be involved in cinnamaldehyde- or capsaicin-induced relaxation, respectively, whereas TRPM3 channels contribute to PregS-induced relaxation, possibly via CGRP-independent mechanisms.


  • Open Access

    Considerations for hormonal therapy in migraine patients: a critical review of current practice

    by Romy van Lohuizen, Jakob Paungarttner, Christian Lampl, Antoinette MaassenVanDenBrink, Linda Al-Hassany

    Migraine, a neurovascular headache disorder, is a leading cause of disability worldwide. Within the multifaceted pathophysiology of migraine, hormonal fluctuations play an evident triggering and exacerbating role, pointing toward the need for identification and proper usage of both existing and new hormonal targets in migraine treatment. With a threefold higher incidence of migraine in women than in men, the authors delve into sex hormone-related events in migraine patients. A comprehensive overview is given of existing hormonal therapies, including oral contraceptives, intrauterine devices, transdermal and subcutaneous estradiol patches, gnRH-agonists, oral testosterone, and 5α reductase inhibitors. The authors discuss their effectiveness and risks, noting their suitability for different patient profiles. Next, novel evolving hormonal treatments, such as oxytocin and prolactin, are explored. Lastly, the authors cover hormonal conditions associated with migraine, such as polycystic ovary syndrome, endometriosis, and transgender persons receiving gender affirming hormone therapy, aiming to provide more personalized and effective solutions for migraine management. Rigorous research into both existing and new hormonal targets, as well as the underlying pathophysiology, is needed to support a tailored approach in migraine treatment, in an ongoing effort to alleviate the impact of migraine on individuals and society.


  • Open Access

    Decreased role of neuropeptides in the microvascular function in migraine patients with polycystic ovary syndrome

    by Linda Al-Hassany, Katie M. Linstra, Cindy Meun, Jeffrey van Den Berg, Eric Boersma, A.H. Jan Danser, Bart C.J.M. Fauser, Joop S.E. Laven, Marieke J.H. Wermer, Gisela M. Terwindt, et al.


  • Open Access

    The sense of stopping migraine prophylaxis

    by Linda Al-Hassany, Hannah S. Lyons, Deirdre M. Boucherie, Fatemeh Farham, Kristin S. Lange, Karol Marschollek, Dilara Onan, Umberto Pensato, Elisabeth Storch, Angelo Torrente, et al.

    Introduction: Migraine prophylactic therapy has changed over recent years with the development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. As new therapies emerged, leading headache societies have been providing guidelines on the initiation and escalation of such therapies. However, there is a lack of robust evidence looking at the duration of successful prophylaxis and the effects of therapy discontinuation. In this narrative review we explore both the biological and clinical rationale for prophylactic therapy discontinuation to provide a basis for clinical decision-making.Methods: Three different literature search strategies were conducted for this narrative review. These include i) stopping rules in comorbidities of migraine in which overlapping preventives are prescribed, notably depression and epilepsy; ii) stopping rules of oral treatment and botox; iii) stopping rules of antibodies targeting the CGRP (receptor). Keywords were utilized in the following databases: Embase, Medline ALL, Web of Science Core collection, Cochran Central Register of Controlled Trials, and Google Scholar.Discussion: Reasons to guide decision-making in stopping prophylactic migraine therapies include adverse events, efficacy failure, drug holiday following long-term administration, and patient-specific reasons. Certain guidelines contain both positive and negative stopping rules. Following withdrawal of migraine prophylaxis, migraine burden may return to pre-treatment level, remain unchanged, or lie somewhere in-between. The current suggestion to discontinue CGRP(-receptor) targeted mAbs after 6 to 12 months is based on expert opinion, as opposed to robust scientific evidence. Current guidelines advise the clinician to assess the success of CGRP(-receptor) targeted mAbs after three months. Based on excellent tolerability data and the absence of scientific data, we propose if no other reasons apply, to stop the use of mAbs when the number of migraine days decreases to four or fewer migraine days per month.There is a higher likelihood of developing side effects with oral migraine preventatives, and so we suggest stopping these drugs according to the national guidelines if they are well tolerated.Conclusion: Translational and basic studies are warranted to investigate the long-term effects of a preventive drug after its discontinuation, starting from what is known about the biology of migraine. In addition, observational studies and, eventually, clinical trials focusing on the effect of discontinuation of migraine prophylactic therapies, are essential to substantiate evidence-based recommendations on stopping rules for both oral preventives and CGRP(-receptor) targeted therapies in migraine.Graphical